
SynBioBeta Speaker
Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Dr. Jose Carlos Garcia-Garcia is a Senior Director and Research Fellow at Procter & Gamble, where he spearheads Corporate Biotechnology within the Disruptive Platforms organization. Originally from Cuba, Dr. Garcia-Garcia obtained his Ph.D. in Biomedical Sciences as a Howard Hughes Predoctoral Fellow and later completed his postdoctoral studies and served in the faculty at The Johns Hopkins University School of Medicine.
In 2010, when P&G launched its Corporate Biotechnology program, Dr. Garcia-Garcia seized the opportunity to channel his passion for applied research into initiatives that enhance consumer health and wellness. Today, he leads the biotechnology-enabled ingredient and product innovation programs across the P&G enterprise, with a project portfolio that includes disruptive and industry-leading innovation efforts in biosurfactants, biopolymers, bioactives, flavors and fragrances. His leadership is shaping a future where the power of biotechnology and biomanufacturing delivers safer, more effective, and more sustainable products for consumers worldwide.
Sessions Featuring
Jose Carlos
This Year
•
-
Planetary Health
Got to Have It: Bio-Derived Ingredients that Drive Meaningful Performance, Delight, and Craveability in Consumer Products
Biotechnology is enabling a new generation of ingredients that elevate both product performance and sustainability. In this fireside chat, leaders from Procter & Gamble will discuss how biotech is being applied across key material classes to enhance consumer products, highlighting innovations behind their latest Native launch and emerging bio-derived ingredients for hair and beauty. The conversation will also explore how biotech platforms are helping shape the future of high-performing, sustainable consumer goods.
Featuring

Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Builds biotech “from microbes to marketplace” at consumer scale.

Amy Trejo
Procter & Gamble Company
Dir. Hair Care Sustain.
Bridges biology and big brands

Mikah Coffindaffer
Procter & Gamble
R&D Director

John Cumbers
SynBioBeta
Founder & CEO
Founder of SynBioBeta: synthetic biology’s global connector and storyteller
•
-
Planetary Health
Got to Have It: Bio-Derived Ingredients that Drive Meaningful Performance, Delight, and Craveability in Consumer Products
Biotechnology is enabling a new generation of ingredients that elevate both product performance and sustainability. In this fireside chat, leaders from Procter & Gamble will discuss how biotech is being applied across key material classes to enhance consumer products, highlighting innovations behind their latest Native launch and emerging bio-derived ingredients for hair and beauty. The conversation will also explore how biotech platforms are helping shape the future of high-performing, sustainable consumer goods.
Featuring

Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Builds biotech “from microbes to marketplace” at consumer scale.

Amy Trejo
Procter & Gamble Company
Dir. Hair Care Sustain.
Bridges biology and big brands

Mikah Coffindaffer
Procter & Gamble
R&D Director

John Cumbers
SynBioBeta
Founder & CEO
Founder of SynBioBeta: synthetic biology’s global connector and storyteller
•
-
Planetary Health
Bio-Engineering the Future of Surfactant Technologies
Surfactants (the molecules that power cleaning, foaming, emulsifying, and conditioning in everyday products) are entering a new era of innovation. Advances in bio-engineering are enabling the design of next-generation surfactants with enhanced performance and reduced environmental impact. By leveraging biologically derived and bio-inspired approaches, researchers and product developers are rethinking how these essential ingredients are produced and formulated. New pathways in fermentation, enzyme engineering, and green chemistry are opening opportunities to create surfactants that are not only more effective, but also better aligned with circularity and nature-positive design principles. This session will explore how bio-engineered surfactants are reshaping formulation science: from new production platforms to novel functional properties, and what it will take to scale these innovations into the next generation of sustainable consumer products.
•
-
Planetary Health
Bio-Engineering the Future of Surfactant Technologies
Surfactants (the molecules that power cleaning, foaming, emulsifying, and conditioning in everyday products) are entering a new era of innovation. Advances in bio-engineering are enabling the design of next-generation surfactants with enhanced performance and reduced environmental impact. By leveraging biologically derived and bio-inspired approaches, researchers and product developers are rethinking how these essential ingredients are produced and formulated. New pathways in fermentation, enzyme engineering, and green chemistry are opening opportunities to create surfactants that are not only more effective, but also better aligned with circularity and nature-positive design principles. This session will explore how bio-engineered surfactants are reshaping formulation science: from new production platforms to novel functional properties, and what it will take to scale these innovations into the next generation of sustainable consumer products.
•
-
AIxBIO
The Programmable Protein Era: How AI Rewrites the Rules of Biomolecules
Biologics and engineered proteins have traditionally evolved through cycles of intuition, screening, and incremental optimization. Today, AI is transforming proteins into programmable systems; governed by learnable patterns across activity, stability, expression, specificity, manufacturability, and environmental performance. This shift is unlocking a new generation of biomolecules, from next-generation therapeutics to sustainable enzymes and functional biological systems, that would have been impossible to design by hand. In this session, leaders from biopharma, industrial biotech, machine learning, and protein engineering will explore how multiparameter optimization, generative modeling, and closed-loop experimental validation are reshaping biomolecular design across domains. From clinical biologics to planetary-scale applications, we examine the shift from trial-and-error to predictive, constraint-driven design, and what it means for R&D timelines, scalability, and real-world impact.
Featuring

Elise de Reus
Cradle
Co-founder
Making proteins an engineering discipline

Peter Clark
Novo Nordisk
VP, CDD
Computational drug-design leader, shipped candidates from CAR-T to peptides.

Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Builds biotech “from microbes to marketplace” at consumer scale.

Luis Cascão Pereira
IFF Health & Biosciences
Head of R&D Ventures & Digital Biology

Fay Lin
GEN
Sr Editor, Technology
•
-
AIxBIO
The Programmable Protein Era: How AI Rewrites the Rules of Biomolecules
Biologics and engineered proteins have traditionally evolved through cycles of intuition, screening, and incremental optimization. Today, AI is transforming proteins into programmable systems; governed by learnable patterns across activity, stability, expression, specificity, manufacturability, and environmental performance. This shift is unlocking a new generation of biomolecules, from next-generation therapeutics to sustainable enzymes and functional biological systems, that would have been impossible to design by hand. In this session, leaders from biopharma, industrial biotech, machine learning, and protein engineering will explore how multiparameter optimization, generative modeling, and closed-loop experimental validation are reshaping biomolecular design across domains. From clinical biologics to planetary-scale applications, we examine the shift from trial-and-error to predictive, constraint-driven design, and what it means for R&D timelines, scalability, and real-world impact.
Featuring

Elise de Reus
Cradle
Co-founder
Making proteins an engineering discipline

Peter Clark
Novo Nordisk
VP, CDD
Computational drug-design leader, shipped candidates from CAR-T to peptides.

Jose Carlos Garcia-Garcia
Procter & Gamble
Sr. Dir., Research Fellow
Builds biotech “from microbes to marketplace” at consumer scale.

Luis Cascão Pereira
IFF Health & Biosciences
Head of R&D Ventures & Digital Biology

Fay Lin
GEN
Sr Editor, Technology
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon







































